The Efficacy And Visual-related Quality Of Life Of Ozurdex For Macular Edema Secondary To Retinal Vein Occlusion

Objective: To research the clinical efficacy,complications and visual-related quality of life(VRQo L)of Ozurdex in the treatment of macular edema related to retinal vein occlusion(RVO-ME).Methods: 30 patients with ME,which had developed secondary to either CRVO(43 %)or BRVO(56 %),were monitored for 6 months after treatment with Ozurdex in the Department of Ophthalmology of our Hospital.We measured the best corrected visual acuity(BCVA),intraocular pressure(IOP),central macular thickness(CMT)at different time after treatment(a week,a month,2months,3months,4months,5months,and 6 months after treatment),and we also measured the Chinese version visual function-related quality of life questionnaire-25(CVRQo L-25)at 3months after treatment and compared them separately with the ones measured before treatment to evaluate the efficacy,adverse reactions and the visual-related quality of life.Result: Generalized estimation equation results showed that BCVA,CMT and IOP all had differences at different time points(P <0.001).A best-corrected visual acuity increase was achieved and CMT decreased in all patients at any time point after the onset of treatment(P <0.001).The changes of BCVA and CMT were the largest in the 2nd month compared to the baseline(P <0.001).The score of CVRQol-25 at 3 months after treatment was markedly higher than that before treatment and then the central retinal thickness decreased and a best-corrected visual acuity increased compared to the baseline level(P <0.01).The score of CVRQo L-25 at 3 months was negatively correlated both with the log BCVA evaluated before treatment and at 3 months after treatment(r =-0.717,-0.746,P <0.001);meanwhile,the score of CVRQo L-25 was also negatively correlated with CMT at 3 months after treatment(r=-0.862,P = 0.001).In63.3% of the patients with RVO-ME,a relapse was observed after a follow-up time of 1 to 3 months and the average recurrence time was(2.8±0.5)months.In19 relapsed patients,16 patients continued intravitreal injection of Ozurdex and 3of them gave up treatment because of poor economy.In follow-up of 6 months,about(2.3±0.4)intravitreal Ozurdex injections per eye was observed.The increase in intraocular pressure was observed at 1wk,1,2,3 months after pretherapy(P <0.05).The mean IOP values reached a peak at 2 months after injection,which rose(7.85±0.32)mm Hg above the baseline level(P <0.05)and decreased to normal at 4 months after treatment.10% of patients had an elevation in IOP above 25 mm Hg,which could be medically controlled and13.3% of patients had cataract formation,two of which needed to surgery.Conclusion: 1.Ozurdex proved to be efficacious with increase in visual acuity and reduction of central retinal thickness and improve the visual function-related quality of life of RVO-ME patients.2.After single injection of Ozurdex,visual acuity benefited for 2-3 months.3.63.3% of the patients relapsed at about 3 months after treatment.Adverse reactions associated to the use of Ozurdex include the formation of cataracts and an increase in intraocular pressure.